Skip to main content
. Author manuscript; available in PMC: 2020 Jun 13.
Published in final edited form as: Cell. 2019 Apr 25;177(7):1903–1914.e14. doi: 10.1016/j.cell.2019.04.004

Figure 6. FUCCI4 cell cycle imaging reveals that combined treatment with olaparib PARP-inhibitor and temozolomide results in rapid G2-cell cycle arrest of human RMS cells engrafted into prkdc−/−, il2rga−/− zebrafish.

Figure 6.

Schematic of FUCCI 4-color cell reporter (A) and experimental design (B). Single fluorescent channels or merged images of RD expressing FUCCI4+ RD RMS cells engrafted peri-ocularly into prkdc−/−, il2rga−/− zebrafish (C-G). Merged images to the right denote cell cycle state for individual cells. High magnification images of cells prior to drug treatment (C) and 7 days after receiving control vehicle (D), temozolomide (TMZ,E), olaparib (F), or TMZ + olaparib (G). Quantification of cell cycle effects in RD ERMS (H) and Rh41 ARMS cells (I). Green asterisks denote statistical differences in numbers of G2-arrested cells when compared to vehicle controls and black asterisks denote differences between single olaparib- or single temozolomide-treated animals when compared to combination-treated zebrafish (*p<0.05 by Fisher’s exact test, n=100 cells analyzed per time point, n=3 animals/condition). Scale bar equals 10μm (C-G). See also Figure S6.